May 2025 in “Cellular Oncology” Blocking both P-cadherin and c-Met can effectively stop head and neck cancer growth.
DOPE:DOPC liposomes can improve targeted cancer drug delivery, reducing side effects and increasing effectiveness.
8 citations
,
September 2015 in “Radiotherapy and oncology” Scalp cooling does not stop hair loss from radiotherapy.
388 citations
,
September 2000 in “Cancer” Doxil's toxicity varies with dose and schedule, and pharmacokinetic guidance can optimize dosing.
November 2023 in “Anticancer Research” Using ultrasound may make cisplatin more effective against cervical cancer in mice.
1 citations
,
January 2018 in “Advances in cancer prevention” Preventing cancer involves lifestyle changes, vaccinations, early screening, and understanding cancer's molecular basis.
December 2021 in “Research Square (Research Square)” Hair growth-promoting nutraceuticals do not block the cancer-fighting effects of tamoxifen and may enhance its action.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
October 2024 in “Journal of the Endocrine Society” Metastatic cervical cancer can cause rare, severe Cushing's syndrome with high risk of death.
28 citations
,
March 2017 in “Scientific Reports” Minoxidil may protect nerves and improve hair quality during paclitaxel treatment.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
Minoxidil and a solvent mixture can prevent hair loss caused by chemotherapy in mice.
2 citations
,
February 2018 in “Journal of bone oncology” Low-dose chemotherapy is safer, more effective, and cost-effective than surgery for treating bone lesions in children.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
August 2024 in “Asian Journal of Research in Chemistry” Repurposing existing drugs can improve cancer treatment but faces challenges.
July 2025 in “Journal of the Pakistan Medical Association” Combining TCA with 5-FU is more effective and safer for treating keloids than TCA alone.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
Permanent micropigmentation can help cancer survivors feel better about themselves by restoring eyebrows lost during chemotherapy.
1 citations
,
January 2009 in “Actas Dermo-Sifiliográficas” Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.
218 citations
,
January 2013 in “The Lancet Oncology” Chemotherapy causes hair loss by damaging hair follicles and stem cells, with more research needed for prevention and treatment.
June 2019 in “Advanced medical journal” Cancer drugs often cause temporary hair, skin, nail, and mouth issues.
Researchers made new compounds that could potentially be developed into anticancer drugs.
June 2018 in “Reactions Weekly” A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.
17 citations
,
July 1995 in “International Journal of Dermatology” Minoxidil helps prevent hair loss from chemotherapy in rats.
October 2024 in “Media Farmasi” Combining soursop leaf extract with doxorubicin may improve breast cancer treatment and reduce side effects.
January 2023 in “Applied sciences” Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
11 citations
,
August 2017 in “Supportive care in cancer” Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.
October 2024 in “Journal of the Endocrine Society” Early detection of ovarian steroid cell tumors is crucial to prevent lasting symptoms.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.